ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.38% | -41.55% | -32.59% | 7.89% | 39.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.64% | -46.01% | -44.01% | -15.95% | 4.25% |
| Operating Income | 36.64% | 46.01% | 44.01% | 15.95% | -4.25% |
| Income Before Tax | 91.27% | 77.92% | 77.59% | -574.65% | -624.75% |
| Income Tax Expenses | 100.07% | 93.89% | 93.89% | -369.19% | -1,169.08% |
| Earnings from Continuing Operations | 90.42% | 76.20% | 75.86% | -601.11% | -596.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.42% | 76.20% | 75.86% | -601.11% | -596.03% |
| EBIT | 36.64% | 46.01% | 44.01% | 15.95% | -4.25% |
| EBITDA | 36.64% | 46.03% | 44.03% | 15.96% | -4.25% |
| EPS Basic | 99.43% | 96.11% | 95.05% | -392.84% | -582.17% |
| Normalized Basic EPS | 96.52% | 93.96% | 86.10% | 44.47% | -130.25% |
| EPS Diluted | 99.43% | 96.11% | 95.05% | -392.84% | -582.17% |
| Normalized Diluted EPS | 96.52% | 93.96% | 86.10% | 44.47% | -130.25% |
| Average Basic Shares Outstanding | 1,040.05% | -97.10% | -98.07% | -98.92% | -99.58% |
| Average Diluted Shares Outstanding | 1,040.05% | -97.10% | -98.07% | -98.92% | -99.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |